ABI-009, an albumin-bound, targeted mTOR inhibitor showed preliminary evidence of safety and efficacy in variety of tumors in a Phase 1 clinical trial.

A registration enabling trial (endpoints agreed with the FDA) in Advanced Malignant PEComa (a rare aggressive form of sarcoma) has completed enrollment.

ABI-009 has Orphan, Fast Track, and Breakthrough Therapy Designations